3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Head & Neck
2
Endocrine
2
Breast
2
NET
1
Lymphoid
1
Genitourinary
1
Conditions
Pancreatic Neuroendocrine Tumors, WHO Grade I-II
1
Interventions
lutetium Lu 177 dotatate
15
Magnetic Resonance Spectroscopy
9
Everolimus
8
gallium Ga 68 dotatate
6
lanreotide
4
cabozantinib
4
Temozolomide
4
Specimen Handling
4
Nivolumab
4
Lutetium-177
4
Lutetium
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
surufatinib
3
olaparib
3
copper dotatate CU-64
3
Somatostatin
3
Injections
3
Ga(III)-DOTATOC
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Capecitabine
3
pembrolizumab
2
fludarabine phosphate
2
fludarabine
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Sunitinib
2
Radiosurgery
2
Octreotide
2
Drug Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Radiofrequency Ablation
×
NET
×
Clear all
NCT05243082
2023-03-30
ERFA-PNET
Oslo University Hospital
Phase NA
Recruiting
20 enrolled